BioBuzz by Workforce Genetics
Horizon Therapeutics Quadruples Space in Maryland to Foster Scientific Innovation
Courtesy of Alexandria Real Estate Equities, Inc.
Published: Jun 14, 2022 By Alex Keown
With a new R&D facility under construction, Horizon Therapeutics’ Bill Rees is excited about the potential of the scientific discovery and cross-functional collaboration he said will lead to new innovations for patients.
Construction on the new state-of-the-art laboratory facility in Rockville, Maryland, has already begun, and the site is expected to be completed by 2024. The new building will provide the company with 192,000-square feet of space for its team, many of whom joined the company, such as Rees, following its 2021 acquisition of rare disease company Viela Bio, which was headquartered in Gaithersburg, Maryland.
Many scientists, including Rees, currently the vice president of translational sciences and also serving as site head for Horizon in Maryland, have provided input into the design of the new space the company is leasing from Alexandria Real Estate Equities. Because scientific innovation will be at the heart of the new space, Horizon wanted to ensure the site will be designed to foster that kind of onsite collaboration.
“We’ve been excited and honored to talk with our employees regarding their interests and thoughts,” Rees told BioSpace. “A large number of our staff are actively involved in the design of the building. The environment must nurture the innovation that we hope it will bring us. By engaging the scientists at all levels of design, it will help us create an environment that fosters that collaboration.”
When the new building is complete in 2024, Horizon will house more than 200 scientists and will have more than quadrupled its footprint in Maryland. Rees excitedly proclaimed the facility “a great and grand endeavor.” While the space will undoubtedly support Horizon’s continued growth, it’s the hope for new, innovative therapies that may be developed there that has enthused Rees so much.
Read the full article at: www.biospace.com